Posts by Mourabit Halima

The latest SEOM-GEMCAD-TTD clinical guidelines offer comprehensive updates on the adjuvant treatment of colon cancer, emphasizing the importance of personalized therapeutic strategies to optimize patient outcomes. These guidelines provide evidence-based recommendations tailored to tumor stage, molecular characteristics, and patient-specific factors, highlighting the shift towards precision medicine in oncology.

Editor's Note: The European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. At this prestigious conference, Dr. Yanhong Deng from the Sixth Affiliated Hospital, Sun Yat-sen…

Editor's Note: Enhanced Recovery After Surgery (ERAS) has become a core concept in modern perioperative management. By implementing a series of evidence-based optimization measures, ERAS aims to reduce or mitigate…

The 2024 Annual Progress Conference on Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) was held in Guangzhou. Since 2015, the highly anticipated Annual Progress…

The MORPHEUS Phase Ib/II trial explores a transformative approach in clinical research by integrating real-world data (RWD) as a hybrid control arm to supplement traditional randomized controlled trials (RCTs) in pancreatic ductal adenocarcinoma (PDAC).

A recent publication in Diagnostics delves into the critical comparison between two cutting-edge molecular techniques—Methyl-BEAMing and Droplet Digital PCR (ddPCR)—for detecting MGMT gene promoter hypermethylation. This biomarker plays a pivotal role in various cancers, particularly glioblastomas, as it helps predict patient response to alkylating agent-based chemotherapy.

The phase II LUMEN study explores the dynamic changes in dosimetric parameters during Peptide Receptor Radionuclide Therapy (PRRT) with [177Lu]Lu-DOTA-TATE for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The study reveals significant variability in absorbed doses and activity concentrations, particularly when comparing tumor sites to organs-at-risk such as the kidneys and red marrow. In pancreatic NETs, absorbed doses in tumors were observed to decrease over the course of treatment cycles, with an approximate reduction of 13% per cycle. Conversely, the kidneys demonstrated an increasing trend in absorbed dose, rising by about 8% per cycle.

The incidence of gastroesophageal cancers is on the rise, driven by factors such as obesity and gastroesophageal reflux. Despite increased awareness and screening efforts, many cases are diagnosed at an advanced, unresectable stage, making effective systemic treatments critical for improving survival and quality of life.

A new international Delphi consensus led by valuable researchers provides crucial guidance on the design and endpoints of clinical trials for Acute Severe Ulcerative Colitis (ASUC). This comprehensive consensus, developed with input from global experts, establishes 30 key statements that define essential aspects of ASUC trial design.